Endpoint Health
Precision-first therapies
Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.
Former Founders
Founder/CSO
Diego Rey, born in Bariloche, Argentina and now based in San Francisco, holds a BS (UCSB) in electrical engineering and PhD (Cornell) in biomedical engineering minoring in applied engineering physics and biophysics. He co-founded GeneWEAVE (acquired by Roche) and Endpoint Health (W19) developing rapid bacterial detection and immune disease therapeutics. Diego was the first bio Visiting Partner at YC. He Angel invests and serves on Cornell advisory councils.
Diego Rey, born in Bariloche, Argentina and now based in San Francisco, holds a BS (UCSB) in electrical engineering and PhD (Cornell) in biomedical engineering minoring in applied engineering physics and biophysics. He co-founded GeneWEAVE (acquired by Roche) and Endpoint Health (W19) developing rapid bacterial detection and immune disease therapeutics. Diego was the first bio Visiting Partner at YC. He Angel invests and serves on Cornell advisory councils.
Jeff Osborn
Founder
Jeff Osborn
Founder
